Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle

On March 5th, a novel immunosuppressive molecule, Siglec-15, was reported in Nature Medicine by Professor Lieping Chen[1][1]. Siglec-15 was reported in a wide variety of tumors. The molecule is not a simple replica of PD-1/PD-L1. Rather, the expressions of Siglec-15 and PD-L1 are mutually exclusive[